Sanofi business relationships

“collaboration: Sanofi recognizes the sales and cost of sales and shares the Alliance's commercial profits with AstraZeneca.” SEC filing

“partner Bristol Myers Squibb (BMS).” SEC filing

“vaccine (developed and distributed in partnership with Merck & Co., Inc.) was approved in 2016 by the EC and is distributed in” SEC filing

“Collaborations: (a) ImmuNext; (b) Regeneron; (c) Recludix; (d) Pfizer” SEC filing

“(1) In partnership with Regeneron.” SEC filing

“(PBMs) - Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group) - have again each excluded” SEC filing

“Sanofi recognizes the sales and cost of sales (purchases of finished products from AstraZeneca) and shares” SEC filing

“(PBMs) - Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group) - have again each excluded” SEC filing

“medicine is licensed to Shionogi Co. Ltd and BMS KK, which sublicensed to Dainippon Pharma Co. Ltd.” SEC filing

“• Following the exclusive licensing agreement on the ProXTen technology platform entered into with Vir Biotechnology in” SEC filing

“• Denali Therapeutics Inc. (2018): collaboration agreement on the development of multiple molecules with the potential to treat” SEC filing

“(PBMs) - Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group) - have again each excluded” SEC filing

“• in partnership with Aily Labs GmbH, we deployed the internal application Plai.” SEC filing

“ALTUVIIIO is developed and commercialized in collaboration with Swedish Orphan Biovitrum AB (Sobi), whose territories include” SEC filing

“• Adagene Inc., a company specializing in the discovery and development of antibody-based therapies (2022) : collaboration” SEC filing

“• Nurix Therapeutics (2020): collaboration to develop novel targeted protein degradation therapies; and” SEC filing

“iv. entered into a collaboration agreement with EVOQ Therapeutics, Inc. (EVOQ) establishing a partnership that enhances our” SEC filing

“• Exclusive licensing agreement with RadioMedix, Inc. and Orano Med for AlphaMedix (SAR447873), a late-stage project” SEC filing

“On February 27, 2017, Sanofi and Lonza announced a strategic partnership in the form of a joint venture (BioAtrium AG) to build” SEC filing

“• Innate Pharma SA (2022) : an expanded collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting” SEC filing

“Beyfortus sales in the US decreased by 21% to $184 million (2024: $232 million; 2023: $87 million), comprised of sales to Sanofi.” SEC filing

“...hepatitis B vaccine ( Recombivax HB , Hepatitis B Vaccine [Recombinant]) and, subject to a collaboration agreement with Sanofi Pasteur MSD, co-promotes a hexavalent vaccine that includes a hepatitis B component ( Vaxelis, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus...” SEC filing

“For example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E.” SEC filing

“Under the terms of the collaboration, Sanofi is generally responsible for funding 80% to 100% of agreed-upon development expenses as incurred.” SEC filing

“For example, Sanofi records product sales for Dupixent in the United States and leads negotiations with payors relating to this product.” SEC filing

“In addition, we rely on Sanofi to lead much of the clinical development efforts, assist with or lead efforts to obtain and maintain regulatory approvals, and lead the commercialization efforts for these products and product candidates.” SEC filing

“In January 2022, we entered into a Collaboration and License Agreement, with Sanofi, or the CLA, and in July 2023 and December 2023, we amended the Collaboration and License Agreement, with such as amended CLA referred to as the Amended CLA.” SEC filing

“For the year ended December 31, 2025, the increase in revenue compared to the prior year was due to revenue recognized from our partnership with Sanofi.” SEC filing

“In collaboration with Sanofi.” SEC filing

“...ollaborators, if any, including milestone, royalty and research and development funding payments from Roche with respect to the development and commercialization of zilebesiran, as well as royalty payments from Novartis and Sanofi related to the commercialization of Leqvio and Qfitlia, respectively;” SEC filing

“We formed a broad strategic alliance with Sanofi in 2014.” SEC filing

“We evaluated the Company's ability to estimate the variable consideration by comparing historical estimates of sales volume and price per vial to actual current-period sales volume and price per vial of product sold by Sanofi.” SEC filing

“Sanofi is our sole customer for ALDURAZYME and is responsible for distributing, marketing, and selling ALDURAZYME to third parties.” SEC filing

“We developed ALDURAZYME through collaboration with Sanofi.” SEC filing

“Sanofi has the exclusive right to distribute, market and sell ALDURAZYME globally and is required to purchase its requirements exclusively from us.” SEC filing

“Beginning in 2025 and continuing during the term of the Sanofi CLA, we and Sanofi began to commercialize the COVID-19 Vaccine products worldwide in accordance with a commercialization plan agreed by us and Sanofi, under which we will continue to supply our existing APA customers and strategic partne...” SEC filing

“Sanofi Collaboration and License Agreement” SEC filing

“As a result, we depend on collaborations with third parties that have established distribution systems and sales forces, including our collaborations with Sanofi and SII, among others.” SEC filing

“For the older adult segment in the U.S., the CDC preferentially recommends Fluzone-HD®, an egg-based high-dose flu vaccine, Flublok®, a recombinant flu vaccine manufactured by Sanofi and Fluad®, an egg-based adjuvanted flu vaccine manufactured by Seqirus.” SEC filing

“In addition, we have entered into licensing agreements with Sanofi in China and Bayer in Japan and expect to establish additional licensing or distribution arrangements in other areas of the world to drive accessibility of our medicines to patients worldwide.” SEC filing

“Under the terms of our license and collaboration agreements, Sanofi is responsible for the development and commercialization of aficamten (to be commercialized as MYQORZO) in China and Bayer is responsible for the development and commercialization of aficamten in Japan.” SEC filing

“We depend on Sanofi for commercialization of MYQORZO in China.” SEC filing

“Subsequent to this side letter, the Company expects to receive no future milestone or royalty payments from Sanofi related to the CNS Products program.” SEC filing

“Sanofi Collaboration and License Agreement” SEC filing

“Our RIPK1 program is subject to our collaboration agreement with Sanofi.” SEC filing

“...ner programs: 1) a single-digit royalty on global net sales of AT220, an Arestat®-enhanced biosimilar product marketed by a global pharmaceutical company; and 2) potential annual technology access fees and milestones from AT292 (efdoralprin alfa/SAR447537/INBRX-101), a partnered program with Sanofi.” SEC filing

“Under the terms of our license agreement with Sanofi, Sanofi may be entitled to receive potential future payments of up to $ 10.0 million upon the achievement of certain event-based milestones and is entitled to receive royalties at tiered percentage rates ranging from 3.0 % to 5.0 % on our future n...” SEC filing

“ModeX and Sanofi are parties to the Sanofi In-License Agreement, pursuant to which ModeX licenses certain intellectual property underlying its Epstein-Barr Virus (EBV) technology.” SEC filing

“1 : Masked TCEs licensed from Sanofi” SEC filing

“Under the terms of the Sanofi Agreement, we will share with Sanofi 20% of certain future collaboration proceeds, including the upfront payment, equity premium and the portion of milestones, profit-share and royalties that exceed amounts already owed to Sanofi.” SEC filing

“Partnered R&D expenses ended in 2023 with the completion of the previous Sanofi agreement, thus R&D Expense is synonymous with 'Unpartnered R&D Expense' since 2024.” SEC filing

“held various regional and global commercialization and alliance management roles at Hoechst Marion Roussel, Aventis, and then Sanofi-Aventis.” SEC filing

“For example, we entered into clinical trial collaborations with our collaborators, including Sanofi, Jazz and the ISTs, to supply evorpacept for clinical trials to advance new combination therapies.” SEC filing

“We also obtained a non-exclusive, worldwide license to use certain other specified know-how licensed to Sanofi by a specified third party to exploit Sanofi Licensed Products solely with respect to Parkinson's disease.” SEC filing

“License Agreement with Sanofi” SEC filing

“We are currently party to license and collaboration agreements with parties such as Sanofi, MedRx, and Cerecor, and we expect to enter into similar strategic transactions in the future.” SEC filing

“For example, we depend on licenses from Sanofi and MedRx for certain intellectual property relating to the development and commercialization of ALTO-101.” SEC filing

“EVT801 was originally discovered by Sanofi SA and was licensed to Evotec SE as part of a broader transaction.” SEC filing

“Upon commercialization of any product utilizing the Sanofi Technology, we will be required to pay to Sanofi tiered royalties in the mid to high single-digit range based upon net sales of licensed products sold by us and our affiliates and sublicensees in a calendar year, subject to adjustments in ce...” SEC filing

“For example, certain trade secrets related to maralixibat are licensed from Pfizer, and patents, patent applications and trade secrets related to volixibat are licensed from Sanofi.” SEC filing

“...for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation ("Novartis"), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“We paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December 2019 related to manufacturing know-how.” SEC filing

“To date, substantially all of our revenue has been derived from our ongoing collaborations and licensing agreements with Neurocrine, Novartis, and Alexion and from our prior collaborations with Sanofi Genzyme, AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company.” SEC filing

“Previously, we have entered into technology licensing agreements with Sanofi and Exelixis to develop antibody-based therapeutics against tumor targets using our SAFEbody technology.” SEC filing

“| | ● | | In July 2025, we announced a clinical trial collaboration agreement with Sanofi to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ADG126 in combination with Sanofi's SAR445877 (PD-1 x IL-15 fusion protein) on adults with advanced solid tumors.” SEC filing

“We are dependent on patents, know-how and proprietary technology, both our own and in-licensed from Sanofi and other collaborators.” SEC filing

“We are collaborating with Sanofi on the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields.” SEC filing

“The Company analyzed the discovery and preclinical research activities as well as the exclusive license grants under the Sanofi Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC 606.” SEC filing

“For example, in June 2019 we entered into a collaboration with Gilead; in December 2019 we entered into a collaboration with Sanofi, which was subsequently expanded and amended in January 2021; and in September 2023 we entered into a collaboration with Seagen Inc. (now a part of Pfizer).” SEC filing

“...hich, if any, of the components of the losmapimod agreement are performance obligations with a customer and concluded that the losmapimod license and the Sanofi territory-specific manufacturing activities are within the scope of ASC 606 because Sanofi is the Company's customer in those transactions.” SEC filing

“Additionally, the Company was entitled to sales milestones and royalties from Sanofi upon future sales of losmapimod in the Sanofi territory, and revenue would have been recognized when the related sales occur.” SEC filing

“Accordingly, we will not recognize additional revenues under the Sanofi collaboration agreement.” SEC filing

“The Company determined that the Sanofi Agreement contained three material promises: (i) the license granted to Sanofi to develop and commercialize losmapimod outside of the United States (the "losmapimod license"); (ii) the parties' joint global development activities for losmapimod; and (iii) the S...” SEC filing

“Under the Sanofi License Agreement, Sanofi provides Rallybio IPE with worldwide exclusive rights to Sanofi's KY1066, which is now referred to as RLYB331.” SEC filing

“SLK is a proprietary Nanobody that was discovered by Ablynx N.V., Belgium, a Sanofi company ("Ablynx"), and previously studied by MHKDG and Avillion LLP ("Avillion") under a 2017 co-development agreement.” SEC filing

“...are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“The Company entered into a Manufacturing & Supply Agreement with SANOFI on August 29, 2025” SEC filing

“In February 2026, SK bioscience announced that it expected topline results from this Phase 3 study to be available in 2027, and that a next-generation PCV candidate, also co-developed with Sanofi, was in preclinical development with clinical trial entry expected in 2026.” SEC filing

“We are currently in discussions with Sanofi, an affiliate of Genzyme, and are in the process of identifying and certifying new suppliers, in each case to fulfill our future supply requirements for sodium hyaluronate.” SEC filing

“In particular, we have entered into license agreements with Sanofi and AbbVie, pursuant to which, among other things, we have secured exclusive licenses for certain intellectual property and know-how relating to CFTR modulator therapies to commercialize certain compounds, patents and proprietary inf...” SEC filing

“...mmercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company, Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme and Roche.” SEC filing

“The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement.” SEC filing

“The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement.” SEC filing

“Under our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories.” SEC filing

“Sanofi also had a right of first refusal with respect to Capeserod out-licensing transactions.” SEC filing

“License Agreement with Sanofi” SEC filing

“...their anti-PD-1/PD-L1 antibodies, including AstraZeneca, BeiGene/Novartis, Bristol-Myers Squibb, Merck, Pfizer in partnership with Merck KGaA, Regeneron in partnership with Sanofi Genzyme and Roche/Genentech, and there are also many other anti-PD-1 and anti-PD-L1 antibodies in clinical development.” SEC filing

“Sanofi collaboration agreement” SEC filing

“...an adeno-associated virus-, or AAV-, medicated gene therapy currently being evaluated in a Phase 1/2 clinical trial by Sanofi S.A., or Sanofi, in the United States and Argentina; and JUV-161, an AKT-signaling activator currently in a Phase 1 single-ascending dose clinical trial in healthy volunteer...” SEC filing

“Under the terms of the license agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration.” SEC filing

“A multi-specific is also being developed in partnership with Sanofi (IPH62).” SEC filing